[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100305600":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":31,"locations":40,"responsibleParty":74,"collaborators":77,"id":81,"slug":82,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":18,"eligibilityCriteria":87,"healthyVolunteers":83,"sex":88,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":18,"studyType":94,"phases":95,"briefSummary":98,"conditions":99,"keywords":101,"overallStatus":43,"whyStopped":18,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},{"fullName":5,"class":6},"Shanghai Jiao Tong University School of Medicine","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"CDMS, Surgery","EXPERIMENTAL","Preoperative chemotherapy using Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) as a single agent performed 45 days before surgery：Cabazitaxel 25 mg\u002Fm2, Docetaxel 35 mg\u002Fm2, Mitoxantrone 4 mg\u002Fm2 or Satraplatin 80 mg\u002Fm2, through intravenous (IV) or oral (Satraplatin) administration. IV or oral administration once every 7 days, totally 4 cycles. There is a 17-day interval between the last dose and surgery.\n\nProcedure: radical prostatectomy surgery.",[13],"Drug: Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin",{"label":15,"type":16,"description":17,"interventionNames":18},"Control","NO_INTERVENTION","No neoadjuvant chemotherapy using CDMS will be done for patients who are diagnosed with localized prostate cancer but subject to direct surgery to radically remove the primary tumor.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin","As preoperative neoadjuvant chemotherapy, drugss including Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) will be administered as a single agent performed 45 days before surgery：Cabazitaxel 25 mg\u002Fm2, Docetaxel 35 mg\u002Fm2, Mitoxantrone 4 mg\u002Fm2 or Satraplatin 80 mg\u002Fm2, through intravenous (IV) or oral (Satraplatin) administration. IV or oral administration once every 7 days, totally 4 cycles. There is a 17-day interval between the last dose and surgery.",[9],[26],"Jevtana, Taxotere, Novantrone, JM216.",[28],{"name":29,"affiliation":5,"role":30},"Yu Sun, Ph.D","PRINCIPAL_INVESTIGATOR",[32,36],{"name":29,"role":33,"phone":34,"phoneExt":18,"email":35},"CONTACT","86-21-54923302","sunyu@sibs.ac.cn",{"name":37,"role":33,"phone":38,"phoneExt":18,"email":39},"Weijun Ma, Ph.D","86-21-54923268","wjma@sibs.ac.cn",[41,60],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Qilu Hospital of Shandong University","RECRUITING","Qingdao","Shandong","266035","China","CN",{"type":50,"coordinates":51},"Point",[52,53],120.38042,36.06488,{"lat":53,"lon":52},[56],{"name":57,"role":33,"phone":58,"phoneExt":18,"email":59},"Jiannan Chen, Ph.D","86-0532-96599654","submarinesuny@yahoo.com",{"facility":61,"status":43,"city":62,"state":18,"zip":63,"country":47,"countryCode":48,"cosmosGeoPoint":64,"geoPoint":68,"contacts":69},"Zhongshan Hospital","Shanghai","200032",{"type":50,"coordinates":65},[66,67],121.45806,31.22222,{"lat":67,"lon":66},[70],{"name":71,"role":33,"phone":72,"phoneExt":18,"email":73},"Qilai Long, Ph.D","86-15821758764","long.qilai@zs-hospital.sh.cn",{"type":30,"investigatorFullName":75,"investigatorTitle":76,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Yu Sun","Professor",[78,80],{"name":79,"class":6},"Fudan University",{"name":42,"class":6},"100305600","phase-2-a-randomised-trial-of-cabazitaxel-docetaxel-mitoxantrone-or-satraplatin-cdms-plus-surgery-for-prostate-cancer-patients-100305600",false,"NCT03258320","A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients","A Phase II-III Study of Neoadjuvant Chemotherapy Involving Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Followed by Surgery for Patients With High Risk Prostate Cancer","Inclusion Criteria:\n\n* 40 ≤ age ≤ 75 years with histologically proven PCa\n* no severe major organ dysfunction\n* WHO performance status of 0 or 1\n* no prior cancer chemotherapy\n* A Clinical Stage ≥ T2c (T2c, N0, M0) of prostate cancer but ideally without diagnosed distant metastasis (according to the 2016 American Joint Committee on Cancer (AJCC) definition of TNM staging system, Staging Manual, Eighth Edition) as determined by a preoperative evaluation that included a pleural computed tomography (CT) scan.\n\nExclusion Criteria:\n\n* age ≥ 76\n* severe major organ dysfunction\n* WHO performance status of \\>1\n* prior cancer chemotherapy\n* Stage IV.","MALE","40 Years","75 Years",{"count":92,"type":93},300,"ESTIMATED","INTERVENTIONAL",[96,97],"PHASE2","PHASE3","Current agents administered in therapeutic regimens of prostate cancer employ different mechanisms to eliminate neoplastic cells by inducing substantial apoptosis and causing tumor regression. Treatment with neoadjuvant chemotherapy before radical prostatectomy may better control the tumor before it has the chance to convert into the disease of castration-resistant prostate cancer (CRPC), which is finally refractory to most modalities of clinical intervention with a clinically lethal nature.",[100],"Prostate Cancer Patients",[102,103,104,105,106,107,108,109],"Cabazitaxel","Docetaxel","Mitoxantrone","Satraplatin","Surgery","Prostate Cancer","Localized","High Risk","2026-01-08",{"date":112,"type":113},"2026-01-12","ACTUAL",{"date":115,"type":113},"2015-01",{"date":117,"type":93},"2027-12",{"name":5,"class":6},2]